Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Multicenter Phase 1b Study of E7046 in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Subjects With Rectum Cancer

Next Previous
X
Search
Trial Profile

An Open-Label Multicenter Phase 1b Study of E7046 in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Subjects With Rectum Cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Palupiprant (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Carcinoma; Rectal cancer
  • Focus Adverse reactions
  • Acronyms PRAER 1
  • Sponsors Adlai Nortye; Eisai Co Ltd

    • Most Recent Events

    • 27 Sep 2022 Results (n=48) of Population pharmacokinetic analysis( from two phase 1 studies NCT02540291 and NCT03152370) to characterize the pharmacokinetic profle of orally administered AN0025 after single and multipledoses in cancer patients presented at the 2022 American College of Clinical Pharmacology Annual Meeting
    • 01 Oct 2021 Status changed from active, no longer recruiting to completed.
    • 02 Jul 2021 Planned primary completion date changed from 1 Aug 2021 to 1 Sep 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top